about
Virus-triggered ubiquitination of TRAF3/6 by cIAP1/2 is essential for induction of interferon-beta (IFN-beta) and cellular antiviral responseGuanidine-Containing Methacrylamide (Co)polymers via aRAFT: Toward a Cell Penetrating Peptide Mimic().Mouse embryonic stem cells have underdeveloped antiviral mechanisms that can be exploited for the development of mRNA-mediated gene expression strategy.Ubiquitin Receptor RPN13 Mediates the Inhibitory Interaction of Diphenyldihaloketones CLEFMA and EF24 With the 26S ProteasomeComparison of Quetiapine Abuse and Misuse Reports to the FDA Adverse Event Reporting System With Other Second-Generation AntipsychoticsInduction of gut proteasome activity in hemorrhagic shock and its recovery by treatment with diphenyldihaloketones CLEFMA and EF24Comparative-effectiveness of ceftaroline and daptomycin as first-line MRSA therapy for patients with sepsis admitted to hospitals in the United States Veterans Health Care SystemRhabdomyolysis Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)Comparing Acute Kidney Injury Reports Among Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System (FAERS)Ubiquitin-Proteasome System in Neurodegenerative DisordersTorsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting SystemHypoglycemia Associated with Antibiotics Alone and in Combination with Sulfonylureas and Meglitinides: An Epidemiologic Surveillance Study of the FDA Adverse Event Reporting System (FAERS)Antipseudomonal monotherapy or combination therapy for older adults with community-onset pneumonia and multidrug-resistant risk factors: a retrospective cohort studyClostridium difficile Infection Risk with Important Antibiotic Classes: An Analysis of the FDA Adverse Event Reporting System
P50
Q33744532-D54B5C75-BB88-4E52-9FCA-B0801B29746EQ34284076-70DE93AF-F443-4927-812A-C5C2FB00FCA8Q37610646-8C8C36C0-FC9F-4C16-B7CF-E6F10944F7CAQ57114402-52D9AB8D-8F35-482B-899E-99BE66488C5DQ64077265-345CF314-2912-473D-A57A-8DA3A16C54FBQ88626354-B95287BA-3FFB-43AF-A895-DC69A5DF830CQ90444703-627CFC96-A76F-45AC-961C-BF19D3819810Q91046334-4100DF09-1F6D-4097-AD5A-C1F646EE1A11Q91132266-97C2532B-3E32-4264-93EA-43FC480D5378Q91561762-2C6B7962-E011-44A2-815F-9656089FA83FQ92155043-2AF662A2-D9BD-4026-9DFF-160682367385Q92165499-0A1B5015-01A8-46B8-AFCF-8068DAA58E7AQ92572711-E6CDBFEF-2CF2-49DB-AF55-1FBB55E3DEC4Q92886668-98D57E85-CDB3-43DC-95E6-5006659EF192
P50
description
researcher ORCID ID = 0000-0001-9239-2125
@en
name
Chengwen Teng
@ast
Chengwen Teng
@en
Chengwen Teng
@es
Chengwen Teng
@nl
type
label
Chengwen Teng
@ast
Chengwen Teng
@en
Chengwen Teng
@es
Chengwen Teng
@nl
prefLabel
Chengwen Teng
@ast
Chengwen Teng
@en
Chengwen Teng
@es
Chengwen Teng
@nl
P1153
57197627514
P31
P496
0000-0001-9239-2125